Citations

Clear

1011 citation(s) found for "Barry, WT".

End‐Stage Renal Disease in African Americans With Lupus Nephritis Is Associated With APOL1
Langefeld, Carl D. , Andringa, Kelly K., Croker, Jennifer A. , Williams, Adrienne H., Garner, Neva E., Birmingham, Daniel J. , Hebert, Lee A., Hicks, Pamela J., Segal, Mark S. , Edberg, Jeffrey C., Brown, Elizabeth E. , Alarcón, Graciela S. , Costenbader, Karen H. , Comeau, Mary E. , Criswell, Lindsey A. , Harley, John B., Sivils, Kathy L., Niewold, Timothy B. , Patel, Neha M., Petri, Michelle , Reveille, John D. , Tsao, Betty P. , Gibson, Keisha L. , Byers, Joyce R., Vinnikova, Anna K., Lea, Janice P. , Julian, Bruce A. , Kimberly, Robert P. , Freedman, Barry I. , Croker, Jennifer A. , Hicks, Pamela J., James, Judith A. , Kamen, Diane L. , Lim, S. Sam , Merrill, Joan T. , Ramsey‐Goldman, Rosalind , Salmon, Jane E.

Mayo Clinic

Arthritis & Rheumatology | October 21, 2013 | Volume: 66 | Issue: 2 | Pages: 390-396

10.1002/art.38220 | PMID 24504811 Get It

Objective Lupus nephritis (LN) is a severe manifestation of systemic lupus erythematosus (SLE) that exhibits familial aggregation and may progress to end‐stage renal disease (ESRD). LN is more prevalent among African Americans than among European Americans. This study was undertaken to investigate the hypothesis that the apolipoprotein L1 gene ( APOL1 ) nephropathy risk alleles G1/G2, common in African Americans and rare in European Americans, contribute to the ethnic disparity in risk. Methods APOL1 G1 and G2 nephropathy alleles were genotyped in 855 African American SLE patients with LN‐ESRD (cases) and 534 African American SLE patients without nephropathy (controls) and tested for association under a recessive genetic model, by logistic regression. Results Ninety percent of the SLE patients were female. The mean ± SD age at SLE diagnosis was significantly lower in LN‐ESRD cases than in SLE non‐nephropathy controls (27.3 ± 10.9 years versus 39.5 ± 12.2 years). The mean ± SD time from SLE diagnosis to development of LN‐ESRD in cases was 7.3 ± 7.2 years. The G1/G2 risk alleles were strongly associated with SLE‐ESRD, with 25% of cases and 12% of controls having 2 nephropathy alleles (odds ratio [OR] 2.57, recessive model P = 1.49 × 10 −9 ), and after adjustment for age, sex, and ancestry admixture (OR 2.72, P = 6.23 × 10 −6 ). The age‐, sex‐, and admixture‐adjusted population attributable risk for ESRD among patients with G1/G2 polymorphisms was 0.26, compared to 0.003 among European American patients. The mean time from SLE diagnosis to ESRD development was ∼2 years earlier among individuals with APOL1 risk genotypes ( P = 0.01). Conclusion APOL1 G1/G2 alleles strongly impact the risk of LN‐ESRD in African Americans, as well as the time to progression to ESRD. The high frequency of these alleles in African Americans with near absence in European Americans explains an important proportion of the increased risk of LN‐ESRD in African Americans.
High data rate transmission of medical images - Prospectus for experiments using the NASA Advanced Communications Technology Satellite
Khandheria, Bijoy K. , Mitchell, Marvin L., Gilbert, Barry K., Bengali, Abdul, Garratt, Kirk N. , Holmes, David R. , Wood, Michael B., Bengali, Abdul R.

Mayo Clinic

16th International Communications Satellite Systems Conference | August 28, 2013 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.2514/6.1996-1071 Get It

Role of Implantable Cardioverter-Defibrillators in Patients With Continuous Flow Ventricular Assist Devices
Boilson, Barry A. , Friedman, Paul A.

Mayo Clinic

Circulation: Arrhythmia and Electrophysiology | August 21, 2013 | Volume: 6 | Issue: 4 | Pages: 663-665

10.1161/circep.113.000818 | PMID 23962858 Get It

Systemic Hypertension in Low-Gradient Severe Aortic Stenosis With Preserved Ejection Fraction
Eleid, Mackram F. , Sorajja, Paul , Nishimura, Rick A. , Sorajja, Paul , Borlaug, Barry A.

Mayo Clinic

Circulation | August 17, 2013 | Volume: 128 | Issue: 12 | Pages: 1349-1353

10.1161/circulationaha.113.003071 | PMID 23956211 Get It

Background— Low-gradient severe aortic stenosis with preserved ejection fraction is an increasingly recognized entity, and symptomatic patients may benefit from aortic valve replacement. However, systemic hypertension frequently coexists with low-gradient severe aortic stenosis, which itself may cause elevated left ventricular (LV) filling pressures with resultant symptoms of dyspnea. Methods and Results— Symptomatic patients with hypertension (aortic systolic pressure >140 mm Hg) and low-gradient (mean gradient <40 mm Hg) severe aortic stenosis (aortic valve area <1 cm 2 ) with preserved ejection fraction (ejection fraction >50%) who underwent invasive hemodynamic catheterization of the left and right sides of the heart received infusion of intravenous sodium nitroprusside to reduce blood pressure and arterial afterload. At baseline, patients had severe hypertension (aortic systolic pressure, 176±26 mm Hg), pulmonary hypertension (mean pressure, 39±12 mm Hg), elevated LV end-diastolic pressure (19±5 mm Hg), and reduced stroke volume (33±8 mL/m 2 ). All measures of afterload were reduced with nitroprusside ( P <0.001 for all). Nitroprusside reduced mean pulmonary artery pressure (25±10 mm Hg) and LV end-diastolic pressure (11±5 mm Hg; P <0.001 for both compared with baseline). Aortic valve area (0.86±0.11 to 1.02±0.16 cm 2 ; P =0.001) and mean gradient (27±5 to 29±6 mm Hg; P =0.02) increased with nitroprusside. Conclusions— Systemic hypertension in low-gradient severe aortic stenosis with preserved ejection fraction is associated with elevated LV filling pressures and pulmonary hypertension. Treatment of hypertension with vasodilator therapy results in a lowering of the total LV afterload, with a decrease in LV filling pressures and pulmonary artery pressures. These findings have important implications for the management of patients with low-gradient severe aortic stenosis with preserved ejection fraction and hypertension.
Global gene expression profiling of pancreatic islets in mice during streptozotocin-induced β-cell damage and pancreatic Glp-1 gene therapy
Tonne, Jason M., Sakuma, Toshie, Deeds, Michael , Munoz-Gomez, Miguel, Barry, Michael A. , Kudva, Yogish C. , Ikeda, Yasuhiro , Barry, Michael A

Mayo Clinic

Disease Models & Mechanisms | July 9, 2013 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1242/dmm.012591 | PMID 23828045 Get It

Summary Streptozotocin (STZ), a glucosamine-nitrosourea compound, has potent genotoxic effects on pancreatic β-cells and is frequently used to induce diabetes in experimental animals. Glucagon-like peptide-1 (GLP-1) has β-cell protective effects and is known to preserve β-cells from STZ treatment. In this study, we analyzed the mechanisms of STZ-induced diabetes and GLP-1-mediated β-cell protection in STZ-treated mice. At 1 week after multiple low-dose STZ administrations, pancreatic β-cells showed impaired insulin expression, while maintaining expression of nuclear Nkx6.1. This was accompanied by significant upregulation of p53-responsive genes in islets, including a mediator of cell cycle arrest, p21 (also known as Waf1 and Cip1). STZ treatment also suppressed expression of a wide range of genes linked with key β-cell functions or diabetes development, such as G6pc2, Slc2a2 (Glut2), Slc30a8, Neurod1, Ucn3, Gad1, Isl1, Foxa2, Vdr, Pdx1, Fkbp1b and Abcc8, suggesting global β-cell defects in STZ-treated islets. The Tmem229B, Prss53 and Ttc28 genes were highly expressed in untreated islets and strongly suppressed by STZ, suggesting their potential roles in β-cell function. When a pancreas-targeted adeno-associated virus (AAV) vector was employed for long-term Glp-1 gene delivery, pancreatic GLP-1 expression protected mice from STZ-induced diabetes through preservation of the β-cell mass. Despite its potent β-cell protective effects, however, pancreatic GLP-1 overexpression showed limited effects on the global gene expression profiles in the islets. Network analysis identified the programmed-cell-death-associated pathways as the most relevant network in Glp-1 gene therapy. Upon pancreatic GLP-1 expression, upregulation of Cxcl13 and Nptx2 was observed in STZ-damaged islets, but not in untreated normal islets. Given the pro-β-cell-survival effects of Cxcl12 (Sdf-1) in inducing GLP-1 production in α-cells, pancreatic GLP-1-mediated Cxcl13 induction might also play a crucial role in maintaining the integrity of β-cells in damaged islets.
Longitudinal Changes in Left Ventricular Stiffness
Redfield, Margaret M. , Melenovský, Vojtěch , Kane, Garvan C. , Karon, Barry L., Jacobsen, Steven J. , Rodeheffer, Richard J. , Borlaug, Barry A. , Melenovský, Vojtěch

Mayo Clinic

Circulation: Heart Failure | June 29, 2013 | Volume: 6 | Issue: 5 | Pages: 944-952

10.1161/circheartfailure.113.000383 | PMID 23811963 Get It

Background— Cross-sectional studies suggest that left ventricular (LV) and arterial elastance (stiffness) increase with age, but data examining longitudinal changes within human subjects are lacking. In addition, it remains unknown whether age-related LV stiffening is merely a reaction to arterial stiffening or caused by other processes. Methods and Results— Comprehensive echo-Doppler cardiography was performed in 1402 subjects participating in a randomly selected community-based study at 2 examinations separated by 4 years. From this population, 788 subjects had adequate paired data to determine LV end-systolic elastance (Ees), end-diastolic elastance (Eed), and effective arterial elastance. Throughout 4 years, blood pressure, arterial elastance, and LV mass decreased, coupled with significantly greater use of antihypertensive medications. However, despite reductions in arterial load, Ees increased by 14% (2.10±0.67–2.26±0.70 mm Hg/mL; P <0.0001) and Eed increased by 8% (0.13±0.03–0.14±0.04 mm Hg/mL; P <0.0001). Increases in Eed were greater in women than men, whereas Ees changes were similar. Age-related increases in Ees and Eed were correlated with changes in body weight, but were similar in subjects with or without cardiovascular disease. Changes in Ees were correlated with Eed ( r =0.5; P <0.0001), but not with other measures of contractility, indicating that the increase in Ees was reflective of passive stiffening rather than enhanced systolic function. Conclusions— Despite reductions in arterial load with medical therapy, LV systolic and diastolic stiffness increase over time in humans, particularly in women. In addition to blood pressure control, therapies targeting load-independent ventricular stiffening may be effective to treat and prevent age-associated cardiovascular diseases, such as heart failure.
Invasive Measures of Afterload in Low Gradient Severe Aortic Stenosis With Preserved Ejection Fraction
Eleid, Mackram F. , Sorajja, Paul , Nishimura, Rick A. , Borlaug, Barry A. , Sorajja, Paul

Mayo Clinic

Circulation: Heart Failure | May 25, 2013 | Volume: 6 | Issue: 4 | Pages: 703-710

10.1161/circheartfailure.112.000164 | PMID 23709656 Get It

Background— The pathophysiology of low flow, low gradient severe aortic stenosis (LGSAS) with preserved ejection fraction is poorly understood. It has been proposed that abnormalities of arterial circulation are a major contributor to this syndrome. Methods and Results— We invasively examined systemic arterial afterload (effective arterial elastance, Ea; total arterial compliance, Ca; and systemic vascular resistance index) in patients with LGSAS (mean gradient, <40 mm Hg; aortic valve area, <1.0 cm 2 ) and preserved ejection fraction (≥50%), and compared these findings with patients with high gradient (≥40 mm Hg) severe aortic stenosis (HGSAS) and moderate AS (mean gradient, <40 mm Hg; aortic valve area, >1.0 cm 2 ). Patients with LGSAS (n=36), HGSAS (n=31), and moderate AS (n=19) were similar with respect to age, sex, body size, symptoms, comorbidities, and ejection fraction. Aortic valve area was similar between groups with LGSAS and HGSAS, but the patients with LGSAS had reduced stroke volume index and cardiac index ( P =0.003 for both). In comparison with patients with HGSAS and moderate AS, measures of afterload, including Ea (4.02±0.98 versus 3.13±0.81 and 3.06±0.79 mm Hg·m 2 /mL; P <0.0001) and systemic vascular resistance index (3116±799 versus 2515±645 and 2380±546 dyn·s·m 2 /cm 5 ; P =0.001), were significantly higher in LGSAS, whereas Ca was lower (0.46±0.16 versus 0.57±0.13 and 0.59±0.19 mL/m 2 per mm Hg; P =0.002). All invasive measures of arterial afterload were related to stroke volume index. Conclusions— Patients with LGSAS and preserved ejection fraction display elevated arterial afterload compared with patients with HGSAS and moderate AS. These findings identify systemic arterial effects that contribute to the hemodynamic presentation in patients with LGSAS and help to further define this entity.
Left Ventricular Dysfunction With Pulmonary Hypertension
Kalogeropoulos, Andreas P. , Georgiopoulou, Vasiliki V., Gheorghiade, Mihai , Borlaug, Barry A. , Gheorghiade, Mihai , Butler, Javed

Mayo Clinic

Circulation: Heart Failure | May 21, 2013 | Volume: 6 | Issue: 3 | Pages: 584-593

10.1161/circheartfailure.112.000096 | PMID 23694772 Get It

Safety of Sports for Athletes With Implantable Cardioverter-Defibrillators
Lampert, Rachel , Olshansky, Brian , Heidbüchel, Hein , Lawless, Christine E., Saarel, Elizabeth V. , Ackerman, Michael J. , Calkins, Hugh , Maron, Barry J. , Scheinman, Melvin M. , Wilkoff, Bruce L. , Zipes, Douglas P. , Berul, Charles I. , Cheng, Alan , Law, Ian H. , Loomis, Michele, Barth, Cheryl , Dziura, James , Cannom, David S. , Estes, N.A. Mark , Link, Mark S. , Marcus, Gregory M. , Brandt, Cynthia , Li, Fangyong , Olshansky, Brian , Law, Ian H , Zipes, Douglas P

Mayo Clinic

Circulation | May 20, 2013 | Volume: 127 | Issue: 20 | Pages: 2021-2030

10.1161/circulationaha.112.000447 | PMID 23690453 Get It

Background— The risks of sports participation for implantable cardioverter-defibrillator (ICD) patients are unknown. Methods and Results— Athletes with ICDs (age, 10–60 years) participating in organized (n=328) or high-risk (n=44) sports were recruited. Sports-related and clinical data were obtained by phone interview and medical records. Follow-up occurred every 6 months. ICD shock data and clinical outcomes were adjudicated by 2 electrophysiologists. Median age was 33 years (89 subjects <20 years of age); 33% were female. Sixty were competitive athletes (varsity/junior varsity/traveling team). A pre-ICD history of ventricular arrhythmia was present in 42%. Running, basketball, and soccer were the most common sports. Over a median 31-month (interquartile range, 21–46 months) follow-up, there were no occurrences of either primary end point—death or resuscitated arrest or arrhythmia- or shock-related injury—during sports. There were 49 shocks in 37 participants (10% of study population) during competition/practice, 39 shocks in 29 participants (8%) during other physical activity, and 33 shocks in 24 participants (6%) at rest. In 8 ventricular arrhythmia episodes (device defined), multiple shocks were received: 1 at rest, 4 during competition/practice, and 3 during other physical activity. Ultimately, the ICD terminated all episodes. Freedom from lead malfunction was 97% at 5 years (from implantation) and 90% at 10 years. Conclusions— Many athletes with ICDs can engage in vigorous and competitive sports without physical injury or failure to terminate the arrhythmia despite the occurrence of both inappropriate and appropriate shocks. These data provide a basis for more informed physician and patient decision making in terms of sports participation for athletes with ICDs.
Primary Care Management of Chronic Stable Angina and Asymptomatic Suspected or Known Coronary Artery Disease: A Clinical Practice Guideline from the American College of Physicians
Snow, Vincenza , Barry, Patricia P., Fihn, Stephan D., Gibbons, Raymond J. , Owens, Douglas K, Williams, Sankey V. , Mottur-Pilson, Christel, Weiss, Kevin B.

Mayo Clinic

Annals of Internal Medicine | April 12, 2013 | Volume: 141 | Issue: 7 | Pages: 562-567

10.7326/0003-4819-141-7-200410050-00014 | PMID 15466774 Get It